San Francisco,4 October
2018: The global cervical
cancer diagnostic market was
valued at USD 7 billion in 2015 and is expected to reach a value of USD 12
billion by 2024, according to a new report by Grand View Research, Inc. The key
driving factors include the rising prevalence of cervical cancer, evolving
screening technology, and various programs that promote routine check up and
screening. According to the data published by the WHO, in 2012, over 270,000
women died due to cervical cancer, majority of which were from the developing
countries. It is one of the most common cancer type diagnosed in women. Some of
the etiological factors are multiple sex partners, and changing lifestyle, such
as drinking & smoking and increased stress levels.
Furthermore, favorable government
initiatives and increasing number of awareness programs are further expected to
promote the market growth in coming few years. The National Cervical Cancer
Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working
towards promoting the necessity for early screening of cervical cancer amongst
mid aged women.
There is an increasing demand for
technologically advanced diagnostic procedures that facilitate the early
intervention of the disease. The industry players are focused on developing
innovative technological solutions for accurate and efficient results.
Advancement in screening techniques, such as use of biomarkers, is gaining
importance. The upsurge in technological developments is anticipated to further
drive industry growth.
On account of increasing adoption of Pap
test, the number of deaths due to cervical cancer has declined significantly in
past few years. It helps detect precancerous lesions at an early state and,
thus, reduces the number of cervical cancer cases. The American Cancer Society
stated that the cervical cancer cases in last 40 years in the U.S. have
declined by more than 50%. Initially, the Pap test screening was carried out
every year which lead to further unnecessary procedures. However, the American
Cancer Society now recommends that women in the age group of 21 to 29 should
undergo Pap test every 3 years.
Access
Research Report of Cervical Cancer
Diagnostic Market @ www.grandviewresearch.com/industry-analysis/cervical-cancer-diagnostics-market
Further
Key Findings from the Study Suggest:
· In 2015, the Pap testing segment held
majority of the market share of 49.6%. The segment’s large share can be
attributed to the high efficiency of the tests in early diagnosis. Also, the
increasing awareness about the impact of early diagnosis contributed to its
growth.
· In 2015, North America was the leading
regional market with a revenue share of 48.3%. The U.S. is a key market in
North America. Growing incidence of cervical cancer coupled with initiatives
undertaken by government agencies in the form of awareness programs pertaining
to the early screening of the disease are key factors for the country’s large
market share.
· Asia Pacific is expected to witness
lucrative growth over the forecast period growing at a CAGR of 9.6%. The
various steps undertaken by governments of developing countries such as India,
China, Philippines, and other in order to improve healthcare infrastructure and
to improve access to healthcare facilities are amongst key factors attributing
to region’s high growth. Also, high prevalence of cancer in developing nations
and increasing consumer awareness levels drive the growth
· This market is presently dominated by a few
key participants such as Becton, Dickinson and Company, F. Hoffmann-La Roche
Ltd, Abbott Laboratories, OncoHealth Corp, Hologic, Inc., QIAGEN, Quest
Diagnostics, Inc and Guided Therapeutics, Inc. The key players focus specially
on developing innovative solutions for diagnosis. For instance, F. Hoffmann-La
Roche Ltd., in 2014, launched automated CINtec PLUS cytology test that
efficiently detects the presence of precancerous cells.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the
Cervical cancer diagnostic market by outsourcing services, application, end
use, and region:
Test type outlook (Market revenue in USD
Billion, 2013 - 2024)
·
Pap Testing
·
HPV Testing
·
Colposcopy
·
Cervical Biopsies
·
Cystoscopy
Regional outlook (Market revenue in USD Billion,
2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Mexico
·
Middle East and Africa
o South Africa
Access Press Release of
Cervical Cancer Diagnostic Market@ www.grandviewresearch.com/press-release/global-cervical-cancer-diagnostics-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business decisions,
we offer market intelligence studies ensuring relevant and fact-based research
across a range of industries, from technology to chemicals, materials and
healthcare.
No comments:
Post a Comment